Stockwinners Market Radar for July 10, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:05 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Twitter (TWTR) has hired U.S. law firm Wachtell, Lipton, Rosen & Katz LLP as it prepares to sue Elon Musk and force him to complete the $44 billion acquisition of the social media company, according to Reuters, citing people familiar with the matter. Musk, the chief executive officer of Tesla (TSLA), on Friday terminated his deal, saying Twitter had failed to provide information about fake accounts on the platform, after which Twitter's chairman, Bret Taylor, vowed a legal fight. 2. A leaked trove of confidential files has revealed the inside story of how Uber (UBER) flouted laws, duped police, exploited violence against drivers and secretly lobbied governments during its aggressive global expansion, The Guardian's Harry Davies, Simon Goodley, Felicity Lawrence, Paul Lewis and Lisa O'Carroll reported. The leak to the Guardian of more than 124,000 documents - known as the Uber files - spans a five-year period when Uber was run by its co-founder Travis Kalanick, who tried to force the cab-hailing service into cities around the world, even if that meant breaching laws and taxi regulations, the authors noted. During the fierce global backlash, the data shows how Uber tried to shore up support by discreetly courting prime ministers, presidents, billionaires, oligarchs and media barons. Leaked messages suggest Uber executives were at the same time under no illusions about the company's law-breaking, with one executive joking they had become "pirates" and another conceding: "We're just fucking illegal." 3. The temperature is rising, but shares of air-conditioning distributor Watsco (WSO) have cooled off, creating an opportunity for investors to buy the stock, Al Root wrote in this week's edition of Barron's. The HVAC distributor operates about 670 stores across the country, from which it sells tens of thousands of products to hundreds of thousands of contractors. Its wares include new AC units, replacement parts, refrigerants, and even Nest thermostats. It's a stable business, one that leads to consistent earnings and sales, and it should be attractive to investors looking to play defense while benefiting from the heat, the author noted. 4. Marvel and Disney's (DIS) "Thor: Love and Thunder" won this weekend's domestic box office with a $143M opening, the best showing of the standalone franchise with Chris Hemsworth as Thor. Overseas, the movie earned $159M for a global total of $302M. Audiences gave "Thor: Love and Thunder" a B+ CinemaScore. 5. Lowe's (LOW), Ford (F), Nordstrom (JWN), Eli Lilly's (LLY), and Altria (MO) saw positive mentions in this week's edition of Barron's.

15:13 EDT Freeline presents data from first cohort of Phase 1/2 dose-confirmation B-LIEVE - Freeline Therapeutics announced the presentation of safety and initial efficacy data from the first cohort of the Phase 1/2 dose-confirmation B-LIEVE trial for FLT180a, the company's AAVS3-based gene therapy candidate for people with hemophilia B, at the International Society on Thrombosis and Haemostasis Congress being held in London, July 9-13, 2022. As of the data cut-off of May 23, 2022, a one-time FLT180a dose of 7.7e11 vg/kg generated a rapid increase of coagulation factor IX, reaching levels in the normal range for the three patients in cohort 1 through days 77, 56 and 36, respectively. Patients stopped FIX prophylaxis and did not require FIX replacement or experience bleeding following treatment with FLT180a. The treatment and the prophylactic immune management regimen were well tolerated. No serious adverse events or infusion reactions were observed, and there has been no evidence of FIX inhibitors. All adverse events were mild, and most were transient. AEs related to immune management were consistent with the known profiles of corticosteroids and tacrolimus. Dosing of cohort two was completed in June, with early results showing a similar initial response to FLT180a. Based on the data from cohort one and consistent with the advice of the independent Data Monitoring Committee of the B-LIEVE trial, patients in cohort two received the same dose of FLT180a and prophylactic immune management regimen that were used in the first cohort. As the data continue to evolve since the data cut-off for cohort one, two patients have experienced a decrease in FIX expression together with a mild and transient increase in liver enzymes. All patients continue to have expression levels above baseline, and no patient has experienced a bleed or required FIX supplementation.

15:00 EDT Data from Phase 3 ATLAS-PPX study presented at ISTH 2022 Congress - Positive data from the Phase 3 ATLAS-PPX study evaluating the efficacy and safety of once-monthly fitusiran in adults and adolescents with severe hemophilia A or B who were previously treated with prior factor or bypassing agent prophylaxis were presented in a late-breaking session at the International Society on Thrombosis and Haemostasis 2022 Congress. The study met the primary endpoint and demonstrated fitusiran prophylaxis significantly reduced bleeding episodes compared to prior factor or BPA prophylaxis. Of the 67 participants exposed to a least one dose of fitusiran, the most common adverse events were increased alanine aminotransferase, nasopharyngitis, and upper respiratory tract infection. Consistent with the previously identified risk of fitusiran, suspected or confirmed thromboembolic events were reported in 2 participants. Sanofi is currently investigating the efficacy and safety of fitusiran under an amended protocol which includes lower doses and a less frequent dosing regimen maintaining an antithrombin target range of 15-35% in all ongoing studies. Fitusiran has the potential to provide prophylactic treatment for all people with hemophilia A or B, with or without inhibitors, with as few as six subcutaneous injections per year.